CAR immune cells: design principles, resistance and the next generation
L Labanieh, CL Mackall - Nature, 2023 - nature.com
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Therapies with genetically modified T cells that express chimeric antigen receptors (CARs)
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
From bench to bedside: the history and progress of CAR T cell therapy
Chimeric antigen receptor (CAR) T cell therapy represents a major breakthrough in cancer
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
[HTML][HTML] Engineering CAR-T cells for next-generation cancer therapy
M Hong, JD Clubb, YY Chen - Cancer cell, 2020 - cell.com
T cells engineered to express chimeric antigen receptors (CARs) with tumor specificity have
shown remarkable success in treating patients with hematologic malignancies and …
shown remarkable success in treating patients with hematologic malignancies and …
CAR T cell therapy for solid tumors: bright future or dark reality?
J Wagner, E Wickman, C DeRenzo, S Gottschalk - Molecular therapy, 2020 - cell.com
Chimeric antigen receptor (CAR) T cell therapy has garnered significant excitement due to
its success for hematological malignancies in clinical studies leading to the US Food and …
its success for hematological malignancies in clinical studies leading to the US Food and …
Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
X Xiao, S Huang, S Chen, Y Wang, Q Sun… - Journal of Experimental & …, 2021 - Springer
Chimeric antigen receptor (CAR) T-cell therapy has yielded impressive outcomes and
transformed treatment algorithms for hematological malignancies. To date, five CAR T-cell …
transformed treatment algorithms for hematological malignancies. To date, five CAR T-cell …
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
K Mestermann, T Giavridis, J Weber, J Rydzek… - Science translational …, 2019 - science.org
Immunotherapy with chimeric antigen receptor (CAR)–engineered T cells can be effective
against advanced malignancies. CAR T cells are “living drugs” that require technologies to …
against advanced malignancies. CAR T cells are “living drugs” that require technologies to …
Programmable eukaryotic protein synthesis with RNA sensors by harnessing ADAR
Programmable approaches to sense and respond to the presence of specific RNAs in
biological systems have broad applications in research, diagnostics, and therapeutics. Here …
biological systems have broad applications in research, diagnostics, and therapeutics. Here …
Teaching an old dog new tricks: next-generation CAR T cells
N Tokarew, J Ogonek, S Endres… - British journal of …, 2019 - nature.com
Adoptive T cell therapy (ACT) refers to the therapeutic use of T cells. T cells genetically
engineered to express chimeric antigen receptors (CAR) constitute the most clinically …
engineered to express chimeric antigen receptors (CAR) constitute the most clinically …
Genetically engineered T cells for cancer immunotherapy
D Li, X Li, WL Zhou, Y Huang, X Liang… - … and Targeted Therapy, 2019 - nature.com
T cells in the immune system protect the human body from infection by pathogens and clear
mutant cells through specific recognition by T cell receptors (TCRs). Cancer immunotherapy …
mutant cells through specific recognition by T cell receptors (TCRs). Cancer immunotherapy …